NCT07380217Recruiting
Use of Mechanical Left ventricuLar Unloading in Complex Higher-risk Indicated Procedures
Source: ClinicalTrials.gov · Last updated 2 Feb 2026
Brief summary (registry, in English)
If there is a narrowing or blockage in the coronary arteries of the heart, the cardiologist may choose to treat this blockage. This is called percutaneous coronary intervention (PCI), which involves both balloon angioplasty and the placement of a stent. PCI is a commonly performed and safe procedure. However, in your case, the procedure is more complicated than usual due to the location and nature of the narrowing, the required technique for the intervention, and the fact that your heart function is reduced. As a result, your PCI will carry a higher risk than usual. During the procedure, balloons are inflated to clear the blockage, and a stent is placed to keep the artery open. This temporarily reduces or even stops the blood and oxygen supply to a large portion of the heart. This moment presents a higher risk for complications, such as low blood pressure or cardiac arrest. As a result, the heart may not pump blood effectively throughout the body, which can lead to oxygen deprivation in other organs. To help the heart in this situation, it is possible to insert a mechanical heart pump during the procedure. This form of support is introduced via an artery in the groin into your left ventricle. The pump helps the heart function and may improve the circulation to the body's organs. On the other hand, the placement of the pump increases the chance of complications. Therefore, there are both potential benefits and risks. It is currently unclear whether PCI with the temporary pump can be performed more safely than without it. This study aims to investigate whether mechanical circulatory support, specifically with the Pulsecath iVAC2L, leads to improved outcomes for patients undergoing high-risk PCI.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 98 (estimated)
- First submitted
- 8 Jan 2026
- Start date
- 25 Jan 2024
- Primary completion date
- 1 Mar 2027
- Lead sponsor
- Amsterdam UMC, location VUmc
- Diseases
- Coronary artery disease
- NCT number
- NCT07380217
What you commit to
- Study type: Interventional
- Planned participants: 98
- From 25 Jan 2024 to the primary completion date, 1 Mar 2027
- 8 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Contraindications for Pulsecath IVAC2L:
- severe aortic regurgitation
- known presence of an LV thrombus (contrast echo/MRI)
- Mechanical aorta valve prosthesis
- severe aortic valve stenosis
- peripheral arterial disease that would preclude placement of the PulseCath iVAC2L device
- Stroke \<3 months
- Major bleeding event \<3 months
- History of bleeding diathesis or known coagulopathy (including heparin-induced thrombo-cytopenia), any recent GU or GI bleed, or will refuse blood transfusions.Renal replacement therapy
Lab values
- Subject belongs to a vulnerable population (defined as individuals with mental disability, persons in nursing homes, impoverished persons, homeless persons, nomads, refugees and those permanently incapable of giving informed consent; vulnerable populations also may include members of a group with a hierarchical structure such as university students, subordinate hospital and laboratory personnel, employees of the Sponsor, members of the armed forces and persons kept in detention).
Other
- Cardiogenic shock defined as either SCAI CSWG stage C-E
- Patient is intubated and mechanically ventilated
- Pregnancy, or suspected thereof.
- BMI \> 35
- Other medical, social, or psychological problems that, in the opinion of the Investigator, compromises the subject's ability to give written informed consent and/or to comply with study procedures.
Who the study is looking for
- Age ≥18 years AND
- Multidisciplinary heart team consensus for high risk PCI +/- MCS AND
- Hemodynamically stable (SCAI A-B) AND
- LVEF \<30% OR LVEF \<35% with moderate MR OR LVEF \<40% with severe MR AND
- Complex left main disease (calcium modifying techniques deemed necessary OR 2-stent techniques, left dominant system) OR equivalent (ostial LAD and RCX) OR last remaining vessel (native).
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (8)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Amsterdam University Medical Center Coordinator of this site? Confirm its status | Amsterdam | Netherlands | Recruiting |
| Zuyderland Coordinator of this site? Confirm its status | Geleen | Netherlands | Recruiting |
| University Medical Center Groningen Coordinator of this site? Confirm its status | Groningen | Netherlands | Recruiting |
| Leiden University Medical Center Coordinator of this site? Confirm its status | Leiden | Netherlands | Recruiting |
| Maastricht University Medical Center Coordinator of this site? Confirm its status | Maastricht | Netherlands | Recruiting |
| Radboud University Medical Center Coordinator of this site? Confirm its status | Nijmegen | Netherlands | Recruiting |
| Haaglanden Medical Center Coordinator of this site? Confirm its status | The Hague | Netherlands | Recruiting |
| University Medical Center Utrecht Coordinator of this site? Confirm its status | Utrecht | Netherlands | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.